David Wood is a lawyer and patent agent in our Calgary office. David practices intellectual property and regulatory law. David is co-chair of the Borden Ladner Gervais Cannabis Industry Focus Group and his regulatory practice is specific to the Canadian medical cannabis industry.
David has advised licensed producers, pre-license entities, technology companies, and other domestic and foreign participants in the Canadian medical cannabis industry in relation to the
Controlled Drugs and Substances Act and its regulations, including the
Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) and the
Narcotic Control Regulations.
David’s intellectual property practice includes:
- drafting and prosecuting patent applications;
- assessing patentability of technology, validity of patents, and infringement of patents, and other patent-related due diligence;
multi-jurisdictional patent portfolio management; and
David has experience with chemical, biochemical, information, and mechanical technologies relating to medical cannabis, medical devices, imaging, oil and gas, and other industries.
During his doctoral work, David characterized a complex between DNA and metal ions using a number of biochemical and biophysical techniques, including surface plasmon resonance spectroscopy, quenching of DNA-tethered fluorophores, and ethidium-based fluorescence assays. David’s education in structural biochemistry, organic chemistry, physical chemistry, plant biochemistry, and natural products chemistry provides a strong technical background for advising clients in the Canadian medical cannabis industry in relation to both intellectual property and regulatory law.
In addition to his technical background, David’s understanding of the ACMPR and other applicable law, and his familiarity with the Canadian medical cannabis industry and its participants, each add value when advising domestic and foreign clients in relation to developing or licensing technology related to the Canadian medical cannabis industry.